Terns Short Long Term Debt vs Current Deferred Revenue Analysis

TERN Stock

USD 6.14 0.15 2.50%

Terns Pharmaceuticals financial indicator trend analysis is much more than just breaking down Terns Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Terns Pharmaceuticals is a good investment. Please check the relationship between Terns Pharmaceuticals Short Long Term Debt and its Current Deferred Revenue accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.

Short Long Term Debt vs Current Deferred Revenue

Short Long Term Debt vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Terns Pharmaceuticals Short Long Term Debt account and Current Deferred Revenue. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Terns Pharmaceuticals' Short Long Term Debt and Current Deferred Revenue is -0.55. Overlapping area represents the amount of variation of Short Long Term Debt that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Terns Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Terns Pharmaceuticals' Short Long Term Debt and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Long Term Debt of Terns Pharmaceuticals are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Short Long Term Debt i.e., Terns Pharmaceuticals' Short Long Term Debt and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

-0.55

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Short Long Term Debt

The total of a company’s short-term and long-term borrowings.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Terns Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Terns Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.At this time, Terns Pharmaceuticals' Tax Provision is very stable compared to the past year. As of the 17th of May 2024, Selling General Administrative is likely to grow to about 41 M, while Issuance Of Capital Stock is likely to drop about 39.5 M.

	2021	2022	2023	2024 (projected)
Interest Income	170K	2.1M	12.9M	13.5M
Net Interest Income	170K	2.1M	12.9M	13.5M

Interest Income Net Interest Income

Terns Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Capital Stock	Net Working Capital
Total Assets		0.66	0.38	1.0	0.75	0.9	0.69	-0.57	-0.82	0.71	0.56	0.47	-0.86	-0.87	1.0	0.76	0.86	-0.76	0.77	0.88	-0.72	0.92	0.88	1.0	-0.78	1.0
Other Current Liab	0.66		0.92	0.64	0.94	0.58	0.88	-0.01	-0.87	0.69	0.07	0.78	-0.58	-0.61	0.62	0.64	0.7	-0.93	0.7	0.71	-0.2	0.57	0.84	0.66	-0.33	0.6
Total Current Liabilities	0.38	0.92		0.35	0.75	0.27	0.7	0.09	-0.63	0.39	0.01	0.65	-0.43	-0.44	0.33	0.41	0.41	-0.81	0.46	0.44	0.14	0.26	0.57	0.38	0.04	0.3
Total Stockholder Equity	1.0	0.64	0.35		0.74	0.9	0.69	-0.56	-0.81	0.71	0.56	0.46	-0.86	-0.87	1.0	0.75	0.86	-0.75	0.76	0.88	-0.74	0.93	0.88	1.0	-0.79	1.0
Other Liab	0.75	0.94	0.75	0.74		0.71	0.93	0.02	-0.92	0.86	0.01	0.83	-0.58	-0.61	0.73	0.69	0.81	-0.92	0.74	0.78	-0.44	0.71	0.95	0.75	-0.56	0.71
Net Tangible Assets	0.9	0.58	0.27	0.9	0.71		0.63	-0.39	-0.89	0.8	0.35	0.46	-0.81	-0.84	0.9	0.74	0.98	-0.73	0.92	0.96	-0.82	0.99	0.84	0.9	-0.92	0.9
Property Plant And Equipment Net	0.69	0.88	0.7	0.69	0.93	0.63		-0.11	-0.83	0.7	0.15	0.95	-0.51	-0.52	0.67	0.47	0.72	-0.86	0.64	0.74	-0.4	0.66	0.92	0.69	-0.5	0.65
Net Debt	-0.57	-0.01	0.09	-0.56	0.02	-0.39	-0.11		0.12	0.15	-0.99	0.09	0.59	0.56	-0.58	-0.17	-0.24	0.13	-0.2	-0.36	0.34	-0.44	-0.21	-0.57	0.27	-0.59
Retained Earnings	-0.82	-0.87	-0.63	-0.81	-0.92	-0.89	-0.83	0.12		-0.88	-0.12	-0.72	0.7	0.75	-0.8	-0.79	-0.96	0.9	-0.94	-0.95	0.55	-0.87	-0.92	-0.81	0.72	-0.79
Accounts Payable	0.71	0.69	0.39	0.71	0.86	0.8	0.7	0.15	-0.88		-0.18	0.62	-0.5	-0.54	0.71	0.77	0.87	-0.73	0.8	0.79	-0.65	0.78	0.86	0.71	-0.8	0.7
Cash	0.56	0.07	0.01	0.56	0.01	0.35	0.15	-0.99	-0.12	-0.18		-0.06	-0.59	-0.56	0.57	0.16	0.21	-0.17	0.18	0.34	-0.27	0.4	0.22	0.56	-0.2	0.58
Non Current Assets Total	0.47	0.78	0.65	0.46	0.83	0.46	0.95	0.09	-0.72	0.62	-0.06		-0.23	-0.25	0.44	0.33	0.57	-0.71	0.53	0.6	-0.22	0.48	0.79	0.46	-0.36	0.42
Non Currrent Assets Other	-0.86	-0.58	-0.43	-0.86	-0.58	-0.81	-0.51	0.59	0.7	-0.5	-0.59	-0.23		1.0	-0.86	-0.55	-0.78	0.78	-0.68	-0.76	0.68	-0.83	-0.7	-0.86	0.64	-0.85
Other Assets	-0.87	-0.61	-0.44	-0.87	-0.61	-0.84	-0.52	0.56	0.75	-0.54	-0.56	-0.25	1.0		-0.86	-0.6	-0.82	0.79	-0.73	-0.8	0.67	-0.85	-0.71	-0.87	0.66	-0.86
Cash And Short Term Investments	1.0	0.62	0.33	1.0	0.73	0.9	0.67	-0.58	-0.8	0.71	0.57	0.44	-0.86	-0.86		0.75	0.86	-0.73	0.76	0.88	-0.75	0.93	0.87	1.0	-0.8	1.0
Common Stock Shares Outstanding	0.76	0.64	0.41	0.75	0.69	0.74	0.47	-0.17	-0.79	0.77	0.16	0.33	-0.55	-0.6	0.75		0.77	-0.58	0.84	0.8	-0.37	0.71	0.67	0.76	-0.6	0.75
Short Term Investments	0.86	0.7	0.41	0.86	0.81	0.98	0.72	-0.24	-0.96	0.87	0.21	0.57	-0.78	-0.82	0.86	0.77		-0.81	0.95	0.97	-0.75	0.97	0.89	0.86	-0.88	0.85
Non Current Liabilities Total	-0.76	-0.93	-0.81	-0.75	-0.92	-0.73	-0.86	0.13	0.9	-0.73	-0.17	-0.71	0.78	0.79	-0.73	-0.58	-0.81		-0.73	-0.78	0.47	-0.73	-0.89	-0.76	0.52	-0.72
Other Current Assets	0.77	0.7	0.46	0.76	0.74	0.92	0.64	-0.2	-0.94	0.8	0.18	0.53	-0.68	-0.73	0.76	0.84	0.95	-0.73		0.97	-0.54	0.88	0.77	0.77	-0.75	0.75
Other Stockholder Equity	0.88	0.71	0.44	0.88	0.78	0.96	0.74	-0.36	-0.95	0.79	0.34	0.6	-0.76	-0.8	0.88	0.8	0.97	-0.78	0.97		-0.65	0.95	0.87	0.88	-0.82	0.87
Total Liab	-0.72	-0.2	0.14	-0.74	-0.44	-0.82	-0.4	0.34	0.55	-0.65	-0.27	-0.22	0.68	0.67	-0.75	-0.37	-0.75	0.47	-0.54	-0.65		-0.85	-0.65	-0.72	0.94	-0.75
Net Invested Capital	0.92	0.57	0.26	0.93	0.71	0.99	0.66	-0.44	-0.87	0.78	0.4	0.48	-0.83	-0.85	0.93	0.71	0.97	-0.73	0.88	0.95	-0.85		0.86	0.92	-0.93	0.93
Property Plant And Equipment Gross	0.88	0.84	0.57	0.88	0.95	0.84	0.92	-0.21	-0.92	0.86	0.22	0.79	-0.7	-0.71	0.87	0.67	0.89	-0.89	0.77	0.87	-0.65	0.86		0.88	-0.74	0.86
Total Current Assets	1.0	0.66	0.38	1.0	0.75	0.9	0.69	-0.57	-0.81	0.71	0.56	0.46	-0.86	-0.87	1.0	0.76	0.86	-0.76	0.77	0.88	-0.72	0.92	0.88		-0.78	1.0
Capital Stock	-0.78	-0.33	0.04	-0.79	-0.56	-0.92	-0.5	0.27	0.72	-0.8	-0.2	-0.36	0.64	0.66	-0.8	-0.6	-0.88	0.52	-0.75	-0.82	0.94	-0.93	-0.74	-0.78		-0.8
Net Working Capital	1.0	0.6	0.3	1.0	0.71	0.9	0.65	-0.59	-0.79	0.7	0.58	0.42	-0.85	-0.86	1.0	0.75	0.85	-0.72	0.75	0.87	-0.75	0.93	0.86	1.0	-0.8

Click cells to compare fundamentals

Terns Pharmaceuticals Account Relationship Matchups

Terns Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	23.9M	92.3M	168.1M	287.0M	268.5M	170.3M
Other Current Liab	3.3M	8.2M	4.7M	6.2M	7.6M	5.8M
Total Current Liabilities	5.0M	22.8M	6.8M	8.5M	11.9M	10.5M
Total Stockholder Equity	4.2M	68.6M	160.3M	276.9M	255.4M	153.6M
Other Liab	630K	877K	947K	1.1M	1.2M	806.7K
Net Tangible Assets	(90.8M)	(117.4M)	172.2M	276.9M	318.5M	334.4M
Property Plant And Equipment Net	961K	1.2M	1.0M	1.8M	1.0M	1.2M
Net Debt	(12.3M)	(62.0M)	(47.7M)	(142.0M)	(79.3M)	(83.3M)
Retained Earnings	(91.9M)	(131.9M)	(182.1M)	(242.4M)	(332.6M)	(316.0M)
Accounts Payable	1.6M	935K	2.1M	1.6M	2.5M	1.8M
Cash	12.3M	74.9M	47.7M	143.2M	79.9M	80.8M
Non Current Assets Total	1.7M	1.4M	1.1M	1.8M	1.1M	1.4M
Non Currrent Assets Other	719K	246K	94K	37K	56K	53.2K
Other Assets	719K	246K	94K	37K	1.0	0.95
Cash And Short Term Investments	19.7M	74.9M	166.0M	283.1M	263.4M	163.9M
Common Stock Shares Outstanding	25.1M	25.1M	25.3M	36.0M	71.3M	37.9M
Short Term Investments	7.3M	0.0	118.3M	139.9M	183.5M	192.7M
Liabilities And Stockholders Equity	23.9M	92.3M	168.1M	287.0M	268.5M	170.3M
Non Current Liabilities Total	14.7M	877K	947K	1.6M	1.2M	1.1M
Other Current Assets	461K	331K	948K	2.1M	4.0M	4.2M
Other Stockholder Equity	1.2M	14.6M	174.6M	520.2M	588.0M	617.4M
Total Liab	19.7M	23.7M	7.8M	10.1M	13.2M	12.2M
Net Invested Capital	(90.8M)	(104.6M)	160.3M	276.9M	255.4M	268.1M
Property Plant And Equipment Gross	961K	1.2M	2.2M	3.2M	2.6M	1.9M
Total Current Assets	22.2M	90.9M	166.9M	285.2M	267.4M	168.9M
Accumulated Other Comprehensive Income	(106K)	(124K)	(338K)	(822K)	(19K)	(20.0K)
Net Working Capital	17.3M	68.0M	160.1M	276.7M	255.5M	158.4M
Property Plant Equipment	961K	1.2M	1.0M	757K	870.6K	924K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Terns Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Terns Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Terns Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Terns Pharmaceuticals Stock:

How To Invest In Terns

Details

Is Terns Stock a good investment?

Details

What is Terns Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.

You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Complementary Tools for Terns Stock analysis

When running Terns Pharmaceuticals' price analysis, check to measure Terns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Terns Pharmaceuticals is operating at the current time. Most of Terns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Terns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Terns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Terns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Fundamental Analysis View fundamental data based on most recent published financial statements
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Technical Analysis Check basic technical indicators and analysis based on most latest market data

Is Terns Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.26)

Revenue Per Share

0.035

Return On Assets

(0.24)

Return On Equity

(0.35)

The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Terns Short Long Term Debt vs Current Deferred Revenue Analysis

Short Long Term Debt vs Current Deferred Revenue

Short Long Term Debt vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Short Long Term Debt

Current Deferred Revenue

Terns Pharmaceuticals fundamental ratios Correlations

Terns Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Terns Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Terns Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity

Cash	- 0.99	Net Debt
Short Term Investments	- 0.96	Retained Earnings
Other Stockholder Equity	- 0.95	Retained Earnings
Other Current Assets	- 0.94	Retained Earnings
Capital Stock	- 0.93	Net Invested Capital
Non Current Liabilities Total	- 0.93	Other Current Liab